These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23186283)

  • 1. Development of porous silicon nanocarriers for parenteral peptide delivery.
    Kovalainen M; Mönkäre J; Kaasalainen M; Riikonen J; Lehto VP; Salonen J; Herzig KH; Järvinen K
    Mol Pharm; 2013 Jan; 10(1):353-9. PubMed ID: 23186283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesoporous silicon (PSi) for sustained peptide delivery: effect of psi microparticle surface chemistry on peptide YY3-36 release.
    Kovalainen M; Mönkäre J; Mäkilä E; Salonen J; Lehto VP; Herzig KH; Järvinen K
    Pharm Res; 2012 Mar; 29(3):837-46. PubMed ID: 22033881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles.
    Liu D; Bimbo LM; Mäkilä E; Villanova F; Kaasalainen M; Herranz-Blanco B; Caramella CM; Lehto VP; Salonen J; Herzig KH; Hirvonen J; Santos HA
    J Control Release; 2013 Sep; 170(2):268-78. PubMed ID: 23756152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanocarriers and the delivered drug: effect interference due to intravenous administration.
    Vlasova MA; Rytkönen J; Riikonen J; Tarasova OS; Mönkäre J; Kovalainen M; Närvänen A; Salonen J; Herzig KH; Lehto VP; Järvinen K
    Eur J Pharm Sci; 2014 Oct; 63():96-102. PubMed ID: 24964293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity.
    Huotari A; Xu W; Mönkäre J; Kovalainen M; Herzig KH; Lehto VP; Järvinen K
    Int J Pharm; 2013 Sep; 454(1):67-73. PubMed ID: 23834832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats.
    Bimbo LM; Sarparanta M; Santos HA; Airaksinen AJ; Mäkilä E; Laaksonen T; Peltonen L; Lehto VP; Hirvonen J; Salonen J
    ACS Nano; 2010 Jun; 4(6):3023-32. PubMed ID: 20509673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery.
    Kilpeläinen M; Mönkäre J; Vlasova MA; Riikonen J; Lehto VP; Salonen J; Järvinen K; Herzig KH
    Eur J Pharm Biopharm; 2011 Jan; 77(1):20-5. PubMed ID: 20965250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photocrosslinked poly(ester anhydride)s for peptide delivery: Effect of oligomer hydrophobicity on PYY3-36 delivery.
    Mönkäre J; Hakala RA; Kovalainen M; Korhonen H; Herzig KH; Seppälä JV; Järvinen K
    Eur J Pharm Biopharm; 2012 Jan; 80(1):33-8. PubMed ID: 21964317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart.
    Tölli MA; Ferreira MP; Kinnunen SM; Rysä J; Mäkilä EM; Szabó Z; Serpi RE; Ohukainen PJ; Välimäki MJ; Correia AM; Salonen JJ; Hirvonen JT; Ruskoaho HJ; Santos HA
    Biomaterials; 2014 Sep; 35(29):8394-405. PubMed ID: 24985734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in porous silicon technology for drug delivery.
    Barnes TJ; Jarvis KL; Prestidge CA
    Ther Deliv; 2013 Jul; 4(7):811-23. PubMed ID: 23883125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradation of inorganic drug delivery systems in subcutaneous conditions.
    Kovalainen M; Kamakura R; Riikonen J; Finnilä M; Nissinen T; Rantanen J; Niemelä M; Perämäki P; Mäkinen M; Herzig KH; Lehto VP
    Eur J Pharm Biopharm; 2018 Jan; 122():113-125. PubMed ID: 29056485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of isotonic solutions and peptide adsorption on zeta potential of porous silicon nanoparticle drug delivery formulations.
    Kaasalainen M; Mäkilä E; Riikonen J; Kovalainen M; Järvinen K; Herzig KH; Lehto VP; Salonen J
    Int J Pharm; 2012 Jul; 431(1-2):230-6. PubMed ID: 22569227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles.
    Kilpeläinen M; Riikonen J; Vlasova MA; Huotari A; Lehto VP; Salonen J; Herzig KH; Järvinen K
    J Control Release; 2009 Jul; 137(2):166-70. PubMed ID: 19345247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics.
    Maher S; Kumeria T; Wang Y; Kaur G; Fathalla D; Fetih G; Santos A; Habib F; Evdokiou A; Losic D
    Adv Healthc Mater; 2016 Oct; 5(20):2667-2678. PubMed ID: 27594524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles.
    Limnell T; Riikonen J; Salonen J; Kaukonen AM; Laitinen L; Hirvonen J; Lehto VP
    Int J Pharm; 2007 Oct; 343(1-2):141-7. PubMed ID: 17600644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular interactions of surface modified nanoporous silicon particles.
    Bimbo LM; Sarparanta M; Mäkilä E; Laaksonen T; Laaksonen P; Salonen J; Linder MB; Hirvonen J; Airaksinen AJ; Santos HA
    Nanoscale; 2012 May; 4(10):3184-92. PubMed ID: 22508528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained-release from nanocarriers: a review.
    Natarajan JV; Nugraha C; Ng XW; Venkatraman S
    J Control Release; 2014 Nov; 193():122-38. PubMed ID: 24862321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functionalization of alkyne-terminated thermally hydrocarbonized porous silicon nanoparticles with targeting peptides and antifouling polymers: effect on the human plasma protein adsorption.
    Wang CF; Mäkilä EM; Bonduelle C; Rytkönen J; Raula J; Almeida S; Närvänen A; Salonen JJ; Lecommandoux S; Hirvonen JT; Santos HA
    ACS Appl Mater Interfaces; 2015 Jan; 7(3):2006-15. PubMed ID: 25539741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms.
    Shahbazi MA; Fernández TD; Mäkilä EM; Le Guével X; Mayorga C; Kaasalainen MH; Salonen JJ; Hirvonen JT; Santos HA
    Biomaterials; 2014 Nov; 35(33):9224-35. PubMed ID: 25123922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro assessment of biopolymer-modified porous silicon microparticles for wound healing applications.
    Mori M; Almeida PV; Cola M; Anselmi G; Mäkilä E; Correia A; Salonen J; Hirvonen J; Caramella C; Santos HA
    Eur J Pharm Biopharm; 2014 Nov; 88(3):635-42. PubMed ID: 25305585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.